Endo T Trial Baseline Nonoral

---
name: endo-t-trial-baseline-nonoral
description: Recommends checking baseline testosterone level and using an approved non-oral preparation (such as transdermal patch, gel, or cream) when initiating a testosterone trial for hypoactive sexual desire disorder (HSDD) in women. Triggered when a clinician plans to start a T trial for HSDD and needs to confirm baseline levels and select an appropriate delivery method.
---

# Suggest baseline testosterone check and approved non-oral formulation for trial

## STEP 1 — Gather Information
Confirm HSDD diagnosis per DSM-5, verify postmenopausal status, and screen for contraindications (pregnancy, androgen-sensitive malignancy, uncontrolled hyperandrogenism).  
**Action:** If criteria are met and no contraindications exist, proceed to order baseline testosterone; otherwise, do not initiate a testosterone trial.

## STEP 2 — Rule In / Rule Out
Determine feasibility of obtaining baseline testosterone (blood draw possible, laboratory access).  
**Action:** If feasible, order serum total and free testosterone (or total T with SHBG if free unavailable); if not feasible, document the limitation and consider deferring the trial or using alternative assessment.

## STEP 3 — Classify or Stratify
Assess local availability of approved non-oral testosterone preparations (transdermal patch, gel, or cream).  
**Action:** If an approved non-oral formulation is available, select it for use; if unavailable, discuss alternatives with the patient or advise against trial initiation due to lack of appropriate product.

## STEP 4 — Decide
Initiate the testosterone trial with the chosen non-oral preparation at a physiological dose (e.g., transdermal patch 300 µg daily) and schedule a follow‑up testosterone level measurement in 3–6 weeks to evaluate for overuse or signs of androgen excess.  
**Action:** Start treatment and arrange follow‑up lab and clinical review.

## Clinical Guardrails / Mimics / Pitfalls
Do not use oral testosterone formulations (risk of hepatic toxicity, insufficient safety data in women); avoid unmonitored supraphysiologic dosing; discontinue immediately if androgenic adverse effects appear (acne, hirsutism, voice deepening, clitoromegaly); never initiate therapy in pregnancy or lactation; avoid formulations designed for men due to risk of overdose.

## Concrete Clinical Example
A 54‑year‑old postmenopausal woman presents with distressing low libido consistent with HSDD. She has no contraindications. Baseline total and free testosterone are ordered. An approved transdermal testosterone patch is available locally. She begins the patch at 300 µg/day and returns in 4 weeks for testosterone level and symptom assessment.

**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260